TrialBlood advances2022
Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease.
Frits van Rhee et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
32 papers cite it
this paperpooled itcites it